Online citations, reference lists, and bibliographies.

Borderline Resectable Pancreatic Cancer: A Consensus Statement By The International Study Group Of Pancreatic Surgery (ISGPS).

Maximilian Bockhorn, Faik Güntac Uzunoglu, Mustapha Adham, Clem W. Imrie, Miroslav N Milićević, Aken A Sandberg, Horacio J. Asbun, Claudio Bassi, Markus W. Büchler, Richard M. Charnley, Kevin Conlon, Laureano Fernández Cruz, Christos G. Dervenis, Abe Fingerhutt, Helmut Friess, Dirk Joan Gouma, Werner Hartwig, Keith D. Lillemoe, Marco Montorsi, John P Neoptolemos, Shailesh V Shrikhande, Kyoichi Takaori, William Traverso, Yogesh Kumar Vashist, Charles M. Vollmer, Charles J Yeo, Jakob Robert Izbicki
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND This position statement was developed to expedite a consensus on definition and treatment for borderline resectable pancreatic ductal adenocarcinoma (BRPC) that would have worldwide acceptability. METHODS An international panel of pancreatic surgeons from well-established, high-volume centers collaborated on a literature review and development of consensus on issues related to borderline resectable pancreatic cancer. RESULTS The International Study Group of Pancreatic Surgery (ISGPS) supports the National Comprehensive Cancer Network criteria for the definition of BRPC. Current evidence supports operative exploration and resection in the case of involvement of the mesentericoportal venous axis; in addition, a new classification of extrahepatic mesentericoportal venous resections is proposed by the ISGPS. Suspicion of arterial involvement should lead to exploration to confirm the imaging-based findings. Formal arterial resections are not recommended; however, in exceptional circumstances, individual therapeutic approaches may be evaluated under experimental protocols. The ISGPS endorses the recommendations for specimen examination and the definition of an R1 resection (tumor within 1 mm from the margin) used by the British Royal College of Pathologists. Standard preoperative diagnostics for BRPC may include: (1) serum levels of CA19-9, because CA19-9 levels predict survival in large retrospective series; and also (2) the modified Glasgow Prognostic Score and the neutrophil/lymphocyte ratio because of the prognostic relevance of the systemic inflammatory response. Various regimens of neoadjuvant therapy are recommended only in the setting of prospective trials at high-volume centers. CONCLUSION Current evidence justifies portomesenteric venous resection in patients with BRPC. Basic definitions were identified, that are currently lacking but that are needed to obtain further evidence and improvement for this important patient subgroup. A consensus for each topic is given.
This paper references
10.1080/13651820600839944
Results of vascular resections during pancreatectomy from two European centres: an analysis of survival and disease-free survival explicative factors.
Mustapha Adham (2006)
10.1002/jso.21769
Is the need for an arterial resection a contraindication to pancreatic resection for locally advanced pancreatic adenocarcinoma? A case-matched controlled study.
P. Bachellier (2011)
10.1007/s00595-007-3661-y
Results of a pancreatectomy with a limited venous resection for pancreatic cancer
Giulio Illuminati (2007)
10.1016/j.gassur.2004.09.046
Pancreaticoduodenectomy with vascular resection: margin status and survival duration
Jennifer Tseng (2004)
10.1002/jso.23044
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Katia T Papalezova (2012)
Isolated Portal Vein Involvement in Pancreatic Adenocarcinoma
L. Harrison (1996)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1186/1477-7819-6-123
Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery?
Matthias Glanemann (2008)
10.1001/archsurg.142.2.172
Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma.
Saburo Fukuda (2007)
10.1245/s10434-009-0408-6
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Mark P. Callery (2009)
10.1245/s10434-011-1560-3
A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma
N. Jamieson (2011)
10.1245/ASO.2006.08.011
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Gauri R. Varadhachary (2006)
10.1001/jamasurg.2013.1058
Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients.
Mathias Worni (2013)
10.1007/s00268-010-0699-6
Vascular Reconstruction During Pancreatoduodenectomy for Ductal Adenocarcinoma of the Pancreas Improves Resectability but does not Achieve Cure
Mehdi Ouaissi (2010)
10.1097/SLA.0b013e318275b7e5
Survival Is Associated With Genetic Variation in Inflammatory Pathway Genes Among Patients With Resected and Unresected Pancreatic Cancer
K. Reid-Lombardo (2013)
10.1002/bjs.7270
Arterial en bloc resection for pancreatic carcinoma.
Maximillian Bockhorn (2011)
10.1245/s10434-012-2809-1
CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
Werner Hartwig (2012)
10.1007/s12032-012-0226-8
Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer
De-Shen Wang (2012)
10.1097/01.sla.0000259391.84304.2b
Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma
Chandrajit P Raut (2007)
10.1245/s10434-009-0413-9
Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
Ross A. Abrams (2009)
10.1016/S0002-9610(03)00173-9
Survival benefits of portal vein resection for pancreatic cancer.
T. Nakagohri (2003)
10.3280/ses2014-002012en
The European Health Report 2012: Charting the Way to Well-being
Regional office for Europe (2013)
10.1016/S1091-255X(01)80023-8
Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas
James F. Pingpank (2001)
10.1245/s10434-012-2348-9
The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma
M. La Torre (2012)
10.1097/00004728-200105000-00002
Vascular Encasement by Pancreatic Cancer: Correlation of CT Findings with Surgical and Pathologic Results
Yoshifuku Nakayama (2001)
10.1016/j.jclinepi.2012.03.013
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations.
Jeff Andrews (2013)
10.1016/j.cgh.2008.09.014
Staging of pancreatic adenocarcinoma by imaging studies.
Jimmie C. Wong (2008)
10.1016/j.jamcollsurg.2007.12.020
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Matthew Harold Katz (2008)
10.1016/j.cell.2011.11.025
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim (2012)
10.1097/SLA.0b013e31823ac299
Arterial Resection During Pancreatectomy for Pancreatic Cancer: A Systematic Review and Meta-Analysis
Nathan Mollberg (2011)
10.1148/radiology.199.3.8637990
Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures.
David Lu (1996)
10.1245/s10434-009-0416-6
Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
Douglas B. Evans (2009)
Response of borderline resectable pancreatic
MH Katz
10.1016/j.cell.2011.12.021
Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches
David A Tuveson (2012)
10.1016/j.ctrv.2012.08.003
The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
Donald C McMillan (2013)
10.1097/SLA.0b013e3181d77369
Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma
N B Jamieson (2010)
10.1007/s00268-012-1461-z
Pancreatectomy Combined with Superior Mesenteric Vein–Portal Vein Resection for Pancreatic Cancer: A Meta-analysis
Y. Zhou (2012)
10.1002/cncr.27636
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.
Matthew Harold Katz (2012)
10.1016/J.PAN.2012.12.048
The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
N B Jamieson (2013)
10.1245/s10434-008-9839-8
Most Pancreatic Cancer Resections are R1 Resections
I. Esposito (2008)
10.3978/j.issn.2078-6891.2011.030
Preoperative therapies for resectable and borderline resectable pancreatic cancer.
Gauri R. Varadhachary (2011)
10.1016/j.surg.2012.07.036
Surgical strategy for patients with pancreatic body/tail carcinoma: who should undergo distal pancreatectomy with en-bloc celiac axis resection?
Ken-ichi Okada (2013)
Positivemobilizationmargins alonedonot influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma
NB Jamieson (2010)
Redefining the R 1 resection in pancreatic can
CS Verbeke (2008)
10.1093/annonc/mds634
VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma.
F. Uzunoglu (2013)
SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)
N. Howlader (2012)
10.1111/j.1477-2574.2008.00013.x
Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).
K. Menon (2009)
10.1080/08858198809527918
[International Union Against Cancer].
Charles D. Sherman (1952)
10.1007/s11605-013-2178-5
Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?
Kaitlyn Jane Kelly (2013)
10.1097/00000658-199602000-00007
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.
George M. Fuhrman (1996)
Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer.
Satoshi Kondo (2000)
10.1097/00000658-200112000-00007
Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial
John P Neoptolemos (2001)
10.1097/01.rct.0000155060.73107.83
Pancreatic Adenocarcinoma: The Different CT Criteria for Peripancreatic Major Arterial and Venous Invasion
Hui Li (2005)
10.1097/00000658-199609000-00010
Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?
L. Harrison (1996)
10.1097/SLA.0b013e31821fd334
Pancreatic Cancer Surgery in the New Millennium: Better Prediction of Outcome
Werner Hartwig (2011)
10.1097/MPA.0b013e318221c595
Clinical Significance of Portal-Superior Mesenteric Vein Resection in Pancreatoduodenectomy for Pancreatic Head Cancer
Sung-Sik Han (2012)
10.1136/bmj.e478
Only women with symptoms need to have their breast implants removed, says government
Adrian O'dowd (2012)
10.1097/PPO.0b013e318278c5b5
Current staging systems for pancreatic cancer.
Betsy L Appel (2012)
10.1007/s00268-001-0070-z
Pancreatectomy Combined with Superior Mesenteric-portal Vein Resection for Adenocarcinoma in Pancreas
C. Shibata (2001)
10.1016/S0090-3671(10)79676-2
Margin Clearance and Outcome in Resected Pancreatic Cancer
Timothy J. Eberlein (2010)
10.1111/j.1477-2574.2009.00055.x
Redefining resection margin status in pancreatic cancer.
C. Verbeke (2009)
10.1148/radiol.2291020582
Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT.
Joel G. Fletcher (2003)
10.1001/archsurg.1963.01310160071012
RADICAL PANCREATODUODENECTOMY AND PORTAL VEIN RESECTION. REPORT OF TWO SUCCESSFUL CASES WITH TRANSPLANTATION OF PORTAL VEIN.
Satoshi Asada (1963)
10.1007/s11605-011-1659-7
A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer
Jerome M Laurence (2011)
10.5555/uri:pii:0039606073902717
Regional resection of cancer of the pancreas: a new surgical approach.
Joseph G. Fortner (1973)
Clinical Practice Guidelines in Oncology . Pancreatic Adenocarcinoma . Version 2 . 2012 ed 2012
HP Siriwardana (2009)
10.1245/s10434-008-0281-8
Does Portal-Superior Mesenteric Vein Invasion Still Indicate Irresectability for Pancreatic Carcinoma?
G. Ramacciato (2008)
10.1002/bjs.5368
Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer.
H. Siriwardana (2006)
10.1002/cncr.24320
A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status.
Christian Wittekind (2009)
10.1097/SLA.0b013e31815aab22
En Bloc Vascular Resection for Locally Advanced Pancreatic Malignancies Infiltrating Major Blood Vessels: Perioperative Outcome and Long-term Survival in 136 Patients
Emre F. Yekebas (2008)
10.1097/SLA.0b013e3181ad657b
Multivisceral Resection for Pancreatic Malignancies: Risk-Analysis and Long-Term Outcome
Werner Hartwig (2009)
Borderline resectable pancreatic cancer: pushing the technical limits of surgery.
Matthew Harold Katz (2013)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1097/01.sla.0000258608.52615.5a
Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Body Cancer: Long-term Results
S. Hirano (2007)
10.1002/bjs.5397
Redefining the R1 resection in pancreatic cancer.
C. Verbeke (2006)
10.1001/archsurg.2007.17
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.
Giovanni Butturini (2008)
10.1038/bjc.2013.332
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
Michael Stotz (2013)
10.1016/j.jamcollsurg.2008.04.033
Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.
Karl Y. Bilimoria (2008)
10.1007/s11605-008-0791-5
Vascular Resection in Pancreatic Cancer Surgery: Survival Determinants
Sascha A. Müller (2008)



This paper is referenced by
10.1007/978-3-319-98944-0_2
Clinical Staging of Pancreatic Cancer with MDCT and MRI
N. Kulkarni (2019)
10.1053/j.tvir.2015.06.006
Percutaneous Approach to Irreversible Electroporation of the Pancreas: Miami Protocol.
Shree R Venkat (2015)
10.1016/j.pharmthera.2015.08.006
State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Cindy Neuzillet (2015)
10.1007/s11605-015-3034-6
Inframesocolic Superior Mesenteric Artery First Approach as an Introductory Procedure of Radical Antegrade Modular Pancreatosplenectomy for Carcinoma of the Pancreatic Body and Tail
Suefumi Aosasa (2015)
10.1016/j.ejso.2016.02.003
The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis.
Salvatore Paiella (2016)
10.1002/9781119188421.CH112
Neoadjuvant Treatment of Pancreatic Cancer
Robert A. Wolff (2018)
10.1002/cncy.21497
Endoscopic ultrasound-guided pancreatic fine-needle aspiration: potential pitfalls in one institution's experience of 1212 procedures.
Joseph P. Bergeron (2015)
10.1016/j.avsg.2019.11.008
Paneled Saphenous Vein Grafts compared to Internal Jugular Vein Grafts in Venous Reconstruction after Pancreaticoduodenectomy.
Joe L Pantoja (2019)
10.1007/s41971-018-0039-5
Beurteilung der Resektabilität beim Pankreaskarzinom
R. Fuegger (2018)
10.1245/s10434-014-4304-3
Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Française de Chirurgie
Jean Robert Delpero (2014)
10.1016/j.canlet.2017.07.012
Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population.
X. Li (2017)
10.1259/bjr.20170165
Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer.
Kenta Sui (2017)
10.1136/bmjopen-2018-028696
Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study
Susanne Roth (2019)
10.1007/978-981-13-0161-2
GI Surgery Annual
Tushar Kanti Chattopadhyay (2018)
10.1007/s11605-018-3995-3
Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety
Yosuke Inoue (2018)
10.3857/roj.2018.00206
Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma
Juan Glinka (2018)
10.1245/s10434-019-07735-8
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma
Hidetoshi Eguchi (2019)
10.1007/978-3-662-47181-4_17
Mesenteric Approach for Pancreaticoduodenectomy
Seiko Hirono (2017)
10.1007/s12029-019-00248-3
The Impact of the Depth of Venous Invasion on Survival Following Pancreatoduodenectomy for Pancreatic Cancer: a Meta-analysis of Available Evidence
C. B. Ratnayake (2019)
10.1371/journal.pone.0163064
Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
Aino N.E. Salmiheimo (2016)
10.1016/j.suc.2017.09.009
Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?
Robert A. Wolff (2018)
10.1007/s00330-017-5258-1
Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT
Sun Kyung Jeon (2017)
10.1016/j.cytogfr.2019.11.001
The role of interleukin-18 in pancreatitis and pancreatic cancer.
Zhiqiang Li (2019)
10.1002/cncr.31936
Borderline resectable pancreatic cancer-At the crossroads of precision medicine.
Matthew Harold Katz (2019)
10.1007/978-3-662-57362-4_19
Palliative Chirurgie des Pankreaskarzinoms
Ulrich F Wellner (2019)
10.1007/s00423-018-1666-1
Incidence and management of arterial injuries during pancreatectomy
D. Kleive (2018)
10.1016/j.surg.2016.02.022
Pancreatoduodenectomy with colon resection for cancer: A nationwide retrospective analysis.
E. Marsman (2016)
10.1007/s00423-015-1305-z
Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion
T. Okabayashi (2015)
10.1177/0300060516665708
Segmental portal/superior mesenteric vein resection and reconstruction with the iliac vein after pancreatoduodenectomy
Xin Zhao (2016)
10.1007/978-3-319-22780-1_13
The Role and Techniques of Vascular Resection
Mark J. Truty (2016)
10.4103/2303-9027.191674
Prominent gastroduodenal artery: Endosonographic sign of celiac artery stenosis
Can Gonen (2016)
10.1007/s00280-016-3121-8
Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial
Ken-ichi Okada (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar